Recall alert: Throw away these 17 salads, salsas due to salmonella concern
Seventeen salad and salsa products containing cucumbers have been recalled because they could be contaminated with salmonella bacteria, according to the U.S. Food and Drug Administration.
The Coastal Companies issued the voluntary recall on May 22 for certain salsas and salads distributed by Fresh Start Produce Sales, Inc. and sold under the brand names East Coast Fresh, TOPS, Wellsley Farms, WEIS, AHOLD, Jack and Olive, Created Fresh and Spring and Sprout.
The products were sold between May 6 and 21 and were distributed in Massachusetts, Vermont, Washington D.C., Ohio, Virginia, Michigan, West Virginia, Delaware, Maryland, Pennsylvania, New Jersey and North Carolina.
Though no illnesses have been linked directly to these products, they may contain cucumbers sold by Bedner Growers, which have been linked to 26 illnesses in 15 states, according to the FDA. Bedner Growers recalled the company's cucumbers on May 19.
Anyone who has purchased one of the recalled products should throw them away rather than returning them.
To see the full list of salad and salsa products that have been recalled, see the FDA's recall notice.
Ford recalls 280,000+ vehicles for brake, steering safety issues
Multi-state salmonella outbreak linked to recalled cucumbers
Public health alert: Listeria found in Big Y, Price Chopper ready-to-eat wrap
Read the original article on MassLive.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the 'Company'), an oncology company integrating novel delivery technology with standard of care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of David B. Patience as Chief Financial Officer, effective July 1, 2025. Mr. Patience succeeds James Young, who stepped down for personal reasons effective May 30, 2025. Dan Giordano, Vice President of Finance for TriSalus, will serve as acting Chief Financial Officer during the transition period. Mr. Young remains available to the Company to support an orderly transition. 'We are thrilled to welcome David to our leadership team,' said Mary Szela, President and CEO of TriSalus Life Sciences. 'David's strong expertise in capital markets and proven track record of financial leadership and operational execution will be invaluable and play a crucial role as we drive our next phase of growth. On behalf of our leadership team, I also thank Jim Young for his service and contributions. We wish him the best in his future endeavors.' Mr. Patience joins TriSalus from Accelerate Diagnostics, where he served as CFO since 2023. He brings extensive experience in leading strategic product portfolio planning, in-depth market analysis of organic and in-organic portfolio opportunities and technical and commercial feasibility analysis of partnerships, mergers and acquisitions. Prior to his time at Accelerate, Mr. Patience held positions with Morgan Stanley's Investment Banking Division, Continental Advisors equity group, and various financial research roles at Nuveen Investments. Mr. Patience holds a Bachelor of Science in Business Administration from the University of Colorado Leeds School of Business and an M.B.A. from the University of Chicago Booth School of Business. About TriSalus TriSalus Life Sciences ® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company's platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company's two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav ® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company's investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during early Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development. Forward Looking Statements Statements made in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company's PEDD drug delivery technology, TriNav ® system and nelitolimod investigational immunotherapy, and the Company's ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward-looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company's clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company's ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, and other risks described in the Company's filings with the Securities and Exchange Commission under the heading 'Risk Factors.' All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law.
Yahoo
2 hours ago
- Yahoo
RFK Jr. has named himself the official arbiter of science
Just two weeks ago, Health and Human Services Secretary Robert F. Kennedy Jr. told Congress that his 'opinions about vaccines are irrelevant' and that nobody should 'take advice' from him about getting them. How quickly things change. In one decision after another, the Trump administration's recent actions have shown that Kennedy, with his poor understanding of basic medicine, has deemed himself the final arbiter of vaccine science in the U.S. On Wednesday, Moderna announced that HHS canceled a $766 million contract with the company to develop potential pandemic influenza strains, including H5N1 bird flu. In the same statement, Moderna also announced that the new vaccine it had been developing against H5 influenza strains, mRNA-1018, had positive results after being tested in 300 adults. As its name indicates, this developmental vaccine used messenger RNA, the same method that was used to develop the Covid-19 vaccine. Earlier this month, Kennedy announced that all new vaccines would need to be developed without using mRNA technology, despite its proven efficacy and safety. He has also demanded that new Covid boosters undergo more rigorous trials than previously required — including full placebo studies — to gain approval for the market. The decision follows last week's announcement from the Food and Drug Administration that annual Covid boosters will be limited moving forward to people 65 and older and/or who have a high risk of severe Covid. According to the FDA, the eligible conditions for the latter range from asthma to pregnancy to diabetes and 'physical inactivity.' The FDA estimates that '100 million to 200 million Americans will have access to vaccines in this manner,' which calls into question the need to limit them at all. In a commentary in the New England Journal of Medicine, FDA Commissioner Marty Makary and vaccine chief Vinay Prasad cited the hesitancy of Americans to get the booster as a reason for pulling back who can access it. In a moment of extreme irony, the pair also blamed the booster program for declining vaccination rates more broadly: There may even be a ripple effect: public trust in vaccination in general has declined, resulting in a reluctance to vaccinate that is affecting even vital immunization programs such as that for measles–mumps–rubella (MMR) vaccination, which has been clearly established as safe and highly effective. In recent years, reduced MMR vaccination rates have been a growing concern and have contributed to serious illness and deaths from measles. It is duplicitous at best to say more study is needed to reassure the public when the science isn't what's in question here. A more apt culprit would most likely be their boss, as Kennedy has been at the forefront of the movement to paint vaccines as unsafe. The anti-vax campaign has helped measles go from a disease of the past to a current concern as outbreaks pop up around the country. Kennedy went even further Tuesday with a surprise announcement that the Centers for Disease Control and Prevention would no longer recommend including the Covid vaccine in its immunization schedule for 'healthy children and healthy pregnant women.' According to The Washington Post, the CDC itself was unaware that this change would be coming before Kennedy posted about it on X. Moreover, the video Kennedy posted, the guidance given internally to CDC staffers and the FDA's commentary last week all contradict one another about exactly who still qualifies for a Covid booster. Kennedy's influence over what the scientists under him can say could strengthen even further in coming days. Earlier this week, he threatened to stop government researchers at the National Institutes of Health and other agencies from publishing their findings in major medical journals like the NEMJ and The Lancet. 'Unless those journals change dramatically, we are going to stop NIH scientists from publishing in them, and we're going to create our own journals in-house,' Kennedy warned in a podcast appearance. It is the antithesis of science that predetermined outcomes be substituted for observation and analysis. It would likewise be naive to suggest that there has never been any sort of political influence on how science is practiced. But Kennedy's blatant positioning of himself as the ultimate judge of how to keep Americans healthy goes beyond the pale. He may say nobody should 'take advice' from him about vaccination — but he's not offering advice anymore. He's telling America how things are going to be from now on. This article was originally published on
Yahoo
2 hours ago
- Yahoo
Combo of cancer therapy drugs increases mice lifespan by 30%
When you buy through links on our articles, Future and its syndication partners may earn a commission. Researchers have found that a cocktail of two cancer drugs can increase the lifespan of mice by up to around 30%, according to a new study. The two drugs, trametinib and rapamycin, were both effective at extending the lives of mice when administered separately, but offered even greater benefits when taken together. They also reduced chronic inflammation and delayed cancer development in the aging mice. Mice are not humans, however, so the new findings don't necessarily mean that people will live longer by taking these drugs (outside of their current prescribed use). But the study authors noted that the drugs, which are approved by the U.S. Food and Drug Administration (FDA), are good candidates for human trials exploring ways to help older people age better. The researchers published their study about the potential longevity benefits of the FDA-approved drugs on May 28 in the journal Nature Aging. "While we do not expect a similar extension to human lifespans as we found in mice, we hope that the drugs we're investigating could help people to stay healthy and disease-free for longer late in life," study co-lead author Linda Partridge, a geneticist at University College London in the U.K. and the Max Planck Institute for Biology of Ageing in Cologne, Germany, said in a statement. Both drugs work by targeting cell communication pathways in the body, which play a critical role in aging and the development of diseases like cancer. Rapamycin inhibits a protein called mTOR, which regulates the division and death of cells and is associated with cancer and other diseases. Trametinib disrupts a molecular pathway called RAS/Mek/Erk, which also plays a role in cancerous cell proliferation — again, useful if you're trying to stop the growth and spread of cancer cells. Related: Heat waves may accelerate the aging process Rapamycin was already known to extend the lifespan of mice, while trametinib has previously been shown to add time to the lifespan of flies. Previous studies have also found that the drugs' separate lifespan-extending effects stack in flies, providing an even greater boost when administered together. However, the new study marks the first time that scientists have combined rapamycin and trametinib to study aging in mammals. The researchers mixed the drugs into the food of lab mice and found that, individually, rapamycin extended the mouse lifespan by 15% to 20% while trametinib extended it by around 5% to 10%. Just like in flies, the drugs proved stronger together, with a cocktail of the two increasing the mouse lifespan by up to 29%, according to the study. RELATED STORIES —Biological secrets of world's oldest woman, Maria Branyas Morera, revealed after death —Single molecule reverses signs of aging in muscles and brains, mouse study reveals —Silent X chromosome genes 'reawaken' in older females, perhaps boosting brain power, study finds To explore the biochemical underpinnings of these effects, the team took tissue samples from the mice and analyzed how the activity of their genes was affected by the two drugs. They found that not only did the mice gain separate benefits from the two different drugs but that, when used in combination, the drug cocktail influenced gene activity differently to when either drug was taken alone, according to the statement. The study highlights that these two drugs could be good candidates for geroprotectors, which are an emerging class of drugs aimed at delaying the onset of diseases and improving the health of older people. However, for now, the researchers plan to optimize the use of trametinib to maximize its benefits while minimizing side effects like weight loss and liver lesions. "Trametinib, especially in combination with rapamycin, is a good candidate to be tested in clinical trials as a geroprotector," co-lead author Sebastian Grönke, a senior postdoctoral researcher at the Max Planck Institute for Biology of Ageing, said in the statement. "We hope that our results will be taken up by others and tested in humans. Our focus is on optimising the use of trametinib in animal models."
